Diabetes mellitus: risk of heart failure more in women than men
Diabetes confers a greater excess risk of heart failure in women than men, according to new research in Diabetologia, the journal of the European Association for the Study of Diabetes.
Type 1 diabetes is associated with a 47% excess risk of heart failure in women compared to men, whilst type 2 diabetes has a 9% excess risk of heart failure for women than men.
It is now recognised that diabetes and heart failure are conditions that often occur together.
Diabetes is not only associated with an increased risk of heart failure, but also with an increased risk of death following diagnosis; and heart failure is the second most common initial presentation of cardiovascular disease in people with type 2 diabetes - more common than myocardial infarction or stroke.
The number of people with heart failure is expected to rise, making earlier prevention and treatment essential.
Accumulating evidence suggests that there are considerable sex differences in the increased risk of a range of cardiovascular diseases associated with diabetes.
Previous analyses have shown that diabetes confers a greater excess risk of coronary heart disease ( CHD ) and stroke, as well as of other non-cardiovascular complications including dementia and cancer, in women compared with men.
A new study has examined possible sex differences in the excess risk of heart failure associated with diabetes mellitus.
The study included observational cohort studies from the PubMed database if they provided sex-specific risk information of the association of diabetes with heart failure in both sexes, and excluded them if they included individuals with underlying diseases, had data for one sex only, or did not take into consideration possible confounders including at least age.
The study pooled the sex-specific relative risks and the women to men ratio of relative risks for heart failure, either fatal or non-fatal, comparing individuals with diabetes to those without the condition, from the relevant research identified.
Of 5991 articles originally identified, 14 studies provided useable data for sex differences in the association between diabetes and the risk of heart failure.
Two of these included data on type 1 diabetes - 2 cohorts providing results for 3,284,123 individuals and 95,129 events.
Data on type 2 diabetes and heart failure were available from 13 studies, involving 47 cohorts that included 11,925,128 individuals and 249,560 heart failure events.
Type 1 diabetes was associated with a 5.15 times higher risk of heart failure in women, and a 3.47 times higher risk in men - meaning a 47% excess relative risk of heart failure for women compared to men.
Type 2 diabetes was associated with a 1.95 times higher risk of heart failure in women, and a 1.74 times higher risk in men - meaning a 9% excess relative risk of heart failure for women compared to men.
According to researchers, there are several potential explanations for the increased excess risk of heart failure in women with diabetes.
Firstly, diabetes may confer a higher risk of coronary heart disease in women than men - CHD is a major cause of heart failure in people with type 2 diabetes and excess risk of coronary heart disease associated with diabetes has previously been shown to be greater in women.
Secondly, sex differences in diabetes management could underpin these associations, as historically women have had poorer glucose control than men.
Another possibility is that under-treatment for women with diabetes may contribute to the development of diabetic cardiomyopathy.
Another potential cause for the difference concerns variation in prolonged high glucose levels prior to full diabetes diagnosis, known as prediabetes, between men and women. This period can be up to two years longer in women and is associated with cardiac dysfunction.
Finally, other cardiovascular risk factors, again reported to be higher in women with diabetes than men, may account for the greater excess risk in women.
In terms of type of diabetes, the excess risk in women was seen to be higher for type 1 compared to type 2. The reason for this difference is unclear, but researchers suggest it may be partly explained by the above mentioned sex differences in the association between diabetes and coronary heart disease.
In a previous study investigators noted a stronger sex difference for type 1 diabetes than type 2 in the association with coronary heart disease.
The strengths of the current study include the large number of participants - data from 14 studies, with 47 cohorts and over 12 million individuals - and the fact that single sex studies were excluded.
Limitations include the possibility of unmeasured confounding factors in the studies used, and the fact that potentially useful data on duration of diabetes, glucose control, use of glucose lowering drugs or type of heart failure was unavailable.
Also, the risk of premature death is higher in men with diabetes than women with diabetes ( and also in the general population ), making men less likely to develop heart failure.
In conclusion, the excess risk of heart failure following a diagnosis of diabetes is high in both sexes, but significantly greater in women than men, highlighting the importance of intensive prevention and treatment of diabetes for women as well as men. ( Xagena )
Source: Diabetologia, 2019
Acid reflux drugs that are sometimes recommended to ease stomach problems during cancer treatment may have an unintended side effect:...
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within...
UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million...
European Commission has approved Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
The European Commission has approved Venclyxto ( Venetoclax ) in combination with Gazyvaro ( Obinutuzumab ) for the treatment of...
Ibrutinib treatment for first-line and relapsed / refractory chronic lymphocytic leukemia: final analysis of PCYC-1102 study
The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia...
Advanced renal cell carcinoma: outcomes based on age in the phase III METEOR trial of Cabozantinib versus Everolimus
Cabozantinib ( Cabometyx ) has improved progression-free survival ( PFS ), overall survival ( OS ) and objective response rate...
FDA: Opdivo plus Yervoy as first-line treatment of patients with metastatic non-small cell lung cancer with PD-L1 expression greater than or equal to 1%
Opdivo ( Nivolumab ) 3 mg/kg plus Yervoy ( Ipilimumab ) 1 mg/kg ( injections for intravenous use ) was...
Metastatic non-small cell lung cancer: Tecentriq has demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy - FDA has approved
The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) as a first-line treatment for...
Rubraca as monotherapy treatment for patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer, treated with androgen receptor-directed therapy and a taxane-based chemotherapy
The FDA ( U.S. Food and Drug Administration ) has approved Rubraca ( Rucaparib ) tablets for the treatment...